Medications for the Treatment of Dysthymic Disorder and Double Depression
|ClinicalTrials.gov Identifier: NCT00234312|
Recruitment Status : Unknown
Verified September 2006 by Oregon Health and Science University.
Recruitment status was: Active, not recruiting
First Posted : October 6, 2005
Last Update Posted : September 11, 2006
|Condition or disease||Intervention/treatment||Phase|
|Depression Dysthymia||Drug: escitalopram and sertraline||Phase 4|
Dysthymic Disorder is a common, chronic type of depression that is often seen as a mild condition and is under-treated. Because of its chronic course, it is often complicated by episodes of major depression and may require long-term treatment.
This is a twelve week study during which daily doses of escitalopram (10-20 mg) or sertraline (50-200 mg) will be given to outpatients meeting criteria for Dysthymic Disorder or Double Depression. Medications will be assigned 1:1 and clinicians will be blinded to treatment. Efficacy will be based on scores for the Hamilton Depression Rating Scale, patient subjective reporting, and clinician observation. The study will have a total of 8 visits over 12 weeks, with a one-week medication taper period at the end. Subjects will have a physical exam, labs, and vital signs monitored at first visit and vital signs monitored at every subsequent visit. Women of childbearing potential must have a negative urine pregnancy test at screening. All subjects will remain on the lowest medication dose for the first four weeks of the study.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||Escitalopram Vs. Sertraline in the Treatment of Dysthymic Disorder and Double Depression|
|Study Start Date :||September 2005|
|Estimated Study Completion Date :||October 2006|
- score on first 17 items of HAM-D Rating Scale 24 item, each visit
- scores on HAM-D 21, HAM-D 24, and Beck Depression Inventory (pt. rated)
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00234312
|United States, Oregon|
|Oregon Health Sciences University|
|Portland, Oregon, United States, 97239|
|Principal Investigator:||Joshua Boverman, MD||Oregon Health and Science University|